<DOC>
	<DOCNO>NCT02940002</DOCNO>
	<brief_summary>To explore efficacy safety four BAY1003803 formulation mean within subject comparison open Psoriasis Plaque Test</brief_summary>
	<brief_title>BAY1003803 Formulation Comparison Open Psoriasis Plaque Test</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Male female ( nonchildbearing potential ) volunteer stable plaquetype psoriasis , otherwise healthy Age : 1864 year Severe disease within last 4 week prior first study drug administration determine investigator Any topical antipsoriatics plaque potentially treat trial ( include corticosteroid , vitamin D analogue , immunomodulators , retinoids , dithranol tar , except salicylic acid ( Pretreatment ) 4 week first treatment and/or plan trial , except allow topical treatment face , ears scalp Systemic treatment depend kind treatment within 4 week 6 month prior and/or plan trial Treatment concomitant medication may affect provoke aggravate psoriasis , e.g . antimalarial drug , lithium , betablockers angiotensinconvertingenzyme inhibitor ( AEC inhibitor ) unless stable dose 3 month study medication initiation Clinicochemical parameter clinically significant deviation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Plaque form psoriasis vulgaris</keyword>
</DOC>